Next Article in Journal
Heterogeneity of Small Intestinal Neuroendocrine Tumors Metastasis: Biologic Patterns of a Series with Virchow’s Node Involvement
Next Article in Special Issue
Overweight and Obesity Determine the Risk for Gastrointestinal Cancer in a Sex-Dependent Manner: A Retrospective Cohort Study of 287,357 Outpatients in Germany
Previous Article in Journal
Glycans as Targets for Drug Delivery in Cancer
Article

Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition

1
Groupe de Recherche sur l’Alcool et les Pharmacodépendances INSERM UMR1247, Centre Universitaire de Recherche en Santé CURS, Université de Picardie Jules Verne, CHU Sud, 80000 Amiens, France
2
Laboratoire HEMATIM EA4666, Centre Universitaire de Recherche en Santé CURS, Université de Picardie Jules Verne, CHU Sud, 80000 Amiens, France
3
Department of Hepatogastroenterology, Centre Hospitalier Universitaire Sud, 80000 Amiens, France
4
Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, 75006 Paris, France
5
Department of Biological Sciences & Engineering, Indian Institute of Technology Palakkad, Palakkad 678623, India
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Hamid Morjani and Mohamed Zaiou
Cancers 2022, 14(4), 910; https://doi.org/10.3390/cancers14040910
Received: 14 January 2022 / Revised: 7 February 2022 / Accepted: 8 February 2022 / Published: 12 February 2022
Sorafenib is a treatment for advanced HCC which demonstrated a poor objective response rate due to important induction of resistance. We demonstrated that induction of acquired-resistance to sorafenib in Huh-7 cell line leads to the loss of SLAMF3 expression, a tumor suppressor receptor in HCC. In these cells, the sorafenib-resistant phenotype is characterized by the increase of aggressiveness and induction of the epithelial-to-mesenchymal transition. Acquired-resistance to sorafenib induce a multipotent mesenchymal stem cells characteristic. Interestingly, SLAMF3 overexpression reversed the epithelial-to-mesenchymal transition and decreased metastatic potential in sorafenib-resistant cells through the control of ERK1/2 and mTOR signaling pathways. SLAMF3 seems to be a theranostics tools to the management of sorafenib treatment.
Background: Acquired resistance to sorafenib in hepatocellular carcinoma (HCC) patients results in poor prognosis. Epithelial-to-mesenchymal transition (EMT) is the major mechanism implicated in the resistance to sorafenib. We have reported the tumor suppressor role of SLAMF3 (signaling lymphocytic activation molecules family 3) in HCC progression and highlighted its implication in controlling the MRP-1 transporter activity. These data suggest the implication of SLAMF3 in sorafenib resistance mechanisms. Methods: We evaluated the resistance to sorafenib in Huh-7 cells treated with progressive doses (Res cells). We investigated the link between acquired resistance to sorafenib and SLAMF3 expression by flow cytometry and Western blot methods. Furthermore, we analyzed the EMT and the stem cell potential of cells resistant to sorafenib. Results: Sorafenib resistance was confirmed in Res cells by analyzing the cell viability in the presence of sorafenib. The mesenchymal transition, in Res cells, was confirmed by high migratory index and the expression of EMT antigens. Interestingly, we found that loss of SLAMF3 expression corresponded to sorafenib-resistant phenotypes. The overexpression of SLAMF3 reversed EMT, decreased metastatic potential and inhibited mTOR/ERK1/2 in Res cells. Conclusions: We propose that rescuing SLAMF3 expression in resistant cells could represent a potential therapeutic strategy to enhance sorafenib efficacy in HCC patients. View Full-Text
Keywords: SLAMF3; sorafenib resistance; EMT; CSCs; HCC SLAMF3; sorafenib resistance; EMT; CSCs; HCC
Show Figures

Graphical abstract

MDPI and ACS Style

Fouquet, G.; Marié, C.; Collet, L.; Vilpoux, C.; Ouled-Haddou, H.; Nguyen-Khac, E.; Bayry, J.; Naassila, M.; Marcq, I.; Bouhlal, H. Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition. Cancers 2022, 14, 910. https://doi.org/10.3390/cancers14040910

AMA Style

Fouquet G, Marié C, Collet L, Vilpoux C, Ouled-Haddou H, Nguyen-Khac E, Bayry J, Naassila M, Marcq I, Bouhlal H. Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition. Cancers. 2022; 14(4):910. https://doi.org/10.3390/cancers14040910

Chicago/Turabian Style

Fouquet, Grégory, Constance Marié, Louison Collet, Catherine Vilpoux, Hakim Ouled-Haddou, Eric Nguyen-Khac, Jagadeesh Bayry, Mickaël Naassila, Ingrid Marcq, and Hicham Bouhlal. 2022. "Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition" Cancers 14, no. 4: 910. https://doi.org/10.3390/cancers14040910

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop